Caught between the rock and the hard place of most-favored nation (MFN) pricing and the threat of a hefty biopharma sector ...

There was a curate’s egg for Sanofi SA from this month’s meeting of the EMA’s Committee for Medicinal Products for Human Use, ...

The full rights to Taysha Gene Therapies Inc.’s lead gene therapy candidate are coming back to the company. In 2022, Astellas ...

Med-tech M&A activity totaled $4.84 billion in September, down slightly from $7.29 billion in July but stronger than August’s ...

Biopharma companies announced $73.38 billion in deals from 240 transactions during the third quarter (Q3) of 2025, bringing ...

Xortx Therapeutics Inc. has entered into a binding term sheet to acquire a renal anti-fibrotic therapeutic program from ...

Boston Scientific Corp. moved to acquire the balance of Nalu Medical Inc. in a $533 million cash deal, expanding its chronic ...

Writing in the Journal of Medicinal Chemistry, researchers from Shenzhen University Medical School and collaborating ...

The U.S. FDA named the first nine recipients of the recently unveiled commissioner’s national priority voucher (CNPV) program ...

Esperion Therapeutics Inc. has nominated ESP-2001 as a preclinical development candidate for the treatment of primary ...

Aicuris Anti-Infective Cures AG is preparing to file for U.S. FDA approval after reporting positive phase III results for ...

Antibody-drug conjugate (ADC) specialist Aimedbio Inc. announced Oct. 16 the signing of a potential $991 million deal with ...